Woodstock Corp Purchases 302 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Woodstock Corp boosted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.1% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,274 shares of the company’s stock after purchasing an additional 302 shares during the period. IDEXX Laboratories accounts for approximately 1.5% of Woodstock Corp’s holdings, making the stock its 19th largest holding. Woodstock Corp’s holdings in IDEXX Laboratories were worth $14,726,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Norges Bank acquired a new position in shares of IDEXX Laboratories during the fourth quarter worth approximately $512,190,000. International Assets Investment Management LLC boosted its holdings in IDEXX Laboratories by 51,631.3% in the fourth quarter. International Assets Investment Management LLC now owns 547,834 shares of the company’s stock valued at $304,075,000 after acquiring an additional 546,775 shares during the last quarter. Capital Research Global Investors acquired a new stake in IDEXX Laboratories in the fourth quarter worth about $135,910,000. TD Asset Management Inc increased its position in IDEXX Laboratories by 178.8% in the fourth quarter. TD Asset Management Inc now owns 260,008 shares of the company’s stock worth $144,317,000 after purchasing an additional 166,751 shares during the period. Finally, Point72 Asset Management L.P. acquired a new position in IDEXX Laboratories during the 4th quarter valued at about $78,001,000. Institutional investors own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on IDXX. Morgan Stanley dropped their price target on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating for the company in a research note on Tuesday, May 14th. William Blair reissued an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. Barclays decreased their price objective on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a research note on Thursday, May 2nd. Finally, StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, June 14th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $580.38.

IDEXX Laboratories Trading Down 1.6 %

IDXX stock traded down $8.12 during midday trading on Thursday, hitting $495.48. 117,071 shares of the company’s stock were exchanged, compared to its average volume of 457,951. IDEXX Laboratories, Inc. has a one year low of $372.50 and a one year high of $583.39. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.16 and a current ratio of 1.57. The company has a market cap of $40.92 billion, a PE ratio of 48.75, a price-to-earnings-growth ratio of 4.11 and a beta of 1.33. The stock’s fifty day moving average price is $500.99 and its 200-day moving average price is $528.55.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Wednesday, May 1st. The company reported $2.81 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.13. IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. The business had revenue of $964.10 million for the quarter, compared to analysts’ expectations of $965.43 million. Research analysts predict that IDEXX Laboratories, Inc. will post 11.03 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Bruce L. Claflin sold 200 shares of the company’s stock in a transaction on Friday, May 17th. The shares were sold at an average price of $540.80, for a total value of $108,160.00. Following the completion of the transaction, the director now directly owns 161 shares of the company’s stock, valued at approximately $87,068.80. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 2.11% of the stock is currently owned by company insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.